CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗卵巢癌：一种有前景的细胞疗法
英文原题：CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
查看英文原题
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
卵巢癌是常见妇科恶性肿瘤之一，预后差、死亡率高。多数患者确诊时已处于III或IV期，全球5年生存率约为25%至47%。手术切除和一线化疗是主要治疗方式，但患者常因化疗耐药而在初始治疗后数年内复发。细胞疗法，尤其是过继T细胞疗法和CAR-T 细胞疗法，在血液系统恶性肿瘤中显示潜力，为卵巢癌提供了另一种免疫治疗方向。然而，CAR-T 用于卵巢癌仍面临多项困难。本综述全面介绍旨在提高临床疗效的CAR-T 工程设计新进展，并讨论克服其在卵巢癌治疗中局限性的策略。
展开英文摘要原文
Ovarian cancer (OC) is among the most common gynecologic malignancies with a poor prognosis and a high mortality rate. Most patients are diagnosed at an advanced stage (stage III or IV), with 5-year survival rates ranging from 25% to 47% worldwide. Surgical resection and first-line chemotherapy are the main treatment modalities for OC.
However, patients usually relapse within a few years of initial treatment due to resistance to chemotherapy. Cell-based therapies, particularly adoptive T-cell therapy and chimeric antigen receptor T (CAR-T) cell therapy, represent an alternative immunotherapy approach with great potential for hematologic malignancies.
However, the use of CAR-T-cell therapy for the treatment of OC is still associated with several difficulties. In this review, we comprehensively discuss recent innovations in CAR-T-cell engineering to improve clinical efficacy, as well as strategies to overcome the limitations of CAR-T-cell therapy in OC.
论文信息
- 作者
- Zhang XW、Wu YS、Xu TM、Cui MH
- 单位
- Department of Gynecology, The Second Hospital of Jilin University, Changchun 130000, China.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Biomolecules2023 Mar 2
- 原文标识
- PubMed 36979400 · DOI 10.3390/biom13030465
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →